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Abstract
Background: The underlying mechanism of HBsAg-negative hepatitis B virus (HBV) infection is notoriously difficult to
elucidate because of the extremely low DNA levels which define the condition. We used a highly efficient amplification
method to overcome this obstacle and achieved our aim which was to identify specific mutations or sequence variations
associated with this entity.
Methods: A total of 185 sera and 60 liver biopsies from HBsAg-negative, HBV DNA-positive subjects or known chronic
hepatitis B (CHB) subjects with HBsAg seroclearance were amplified by rolling circle amplification followed by full-length
HBV genome sequencing. Eleven HBsAg-positive CHB subjects were included as controls. The effects of pivotal mutations
identified on regulatory regions on promoter activities were analyzed.
Results: 22 and 11 full-length HBV genomes were amplified from HBsAg-negative and control subjects respectively. HBV
genotype C was the dominant strain. A higher mutation frequency was observed in HBsAg-negative subjects than controls,
irrespective of genotype. The nucleotide diversity over the entire HBV genome was significantly higher in HBsAg-negative
subjects compared with controls (p= 0.008) and compared with 49 reference sequences from CHB patients (p= 0.025). In
addition, HBsAg-negative subjects had significantly higher amino acid substitutions in the four viral genes than controls (all
p,0.001). Many mutations were uniquely found in HBsAg-negative subjects, including deletions in promoter regions
(13.6%), abolishment of pre-S2/S start codon (18.2%), disruption of pre-S2/S mRNA splicing site (4.5%), nucleotide
duplications (9.1%), and missense mutations in ‘‘a’’ determinant region, contributing to defects in HBsAg production.
Conclusions: These data suggest an accumulation of multiple mutations constraining viral transcriptional activities
contribute to HBsAg-negativity in HBV infection.
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Introduction
Hepatitis B virus (HBV) infection leads to a wide spectrum of
liver injuries, ranging from acute self-limiting infection and
fulminant hepatitis to chronic hepatitis, liver cirrhosis and
hepatocellular carcinoma (HCC) [1]. The viral genome contains
four partially overlapping open reading frames (ORFs) (pre-S/S,
pre-C/C, P and X) [2]. HBV infection is usually diagnosed when
the circulating HBV surface antigen (HBsAg) is detected.
Spontaneous loss of HBsAg is a rare event in chronic hepatitis B
(CHB) infection [3–6]. Loss of serum HBsAg is also observed in
patients receiving treatment for CHB with interferon and
nucleoside/nucleotide analogues [7,8].
Although the continued presence of detectable HBsAg in serum
is a prominent feature of HBsAg-positive CHB infection or overt
CHB infection, HBsAg seroclearance may not signify eradication
of HBV. The introduction of sensitive HBV DNA detection tests
has revealed the existence of HBsAg-negative HBV infection. This
new entity of HBV infection is defined as ‘‘the presence of viral
DNA in the liver (with detectable or undetectable HBV DNA in
the serum) of individuals testing negative for the HBsAg’’ [9,10].
Some of these subjects may be people with or without prior
medical history of HBV infection can develop to the occult phase
[11]. All these scenarios are collectively termed occult hepatitis B
infection (OBI) [10].
Clinical evidence reveals that there is generally no reduction in
the risk for HCC in CHB patients with HBsAg seroclearance
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compared with those who are persistently positive for HBsAg [12–
14]. The virological features and the mechanisms leading to OBI
are still unclear, although viral mutations may be one of the
significant factors. Many attempts have been done to analyze
HBV genome sequences amplified from OBI patients. Most
studies focused on searching for mutations on a fragment of HBV
genome (mainly the region coding for HBsAg). This is due to the
extremely low viral DNA levels in blood or liver tissue in these
patients rendering amplification difficult. Mutations have been
found in various regions of the HBV genome and may be
associated with OBI: (1) mutations in the surface protein affecting
antigen detection [15–17]; (2) deletions in the pre-S1 region that
impair HBV packaging [18,19]; (3) various mutations in viral
regulatory regions that cause decreased in HBsAg expression and/
or viral replication [20,21]; and (4) mutations affecting post-
translational protein production [20,22]. In addition to these
potential mechanisms, epigenetic modifications of the HBV
genome are also suggested to play a significant role in OBI [23].
However, these studies mainly evaluated viral coding sequences, in
particular, the different surface proteins. Owing to the complex
organization of viral genome and also the efficient regulation, it is
important to study mutations in both gene coding regions as well
as the regulatory regions. It remains elusive as to which mutations
and variations can lead to OBI. Thus, comprehensive whole
genome analyses are still needed.
In the present study, we adopted a highly efficient amplification
method, rolling circle amplification (RCA) to amplify full-length
HBV genome from sera and liver biopsies of OBI subjects. We
primarily aimed at analyzing sequence variations of complete
HBV genome in subjects with OBI. The secondary aim was to
analyze the effect of pivotal mutations identified on regulatory
region(s) on promoter activities of the viral genes.
Materials and Methods
Patients and Samples
A total of 185 serum samples (156 from CHB patients with
HBsAg seroclearance; 29 from HBsAg-negative patients with
detectable HBV DNA at the first presentation) and 60 liver
biopsies (21 from CHB patients with HBsAg seroclearance;
39 from HBsAg-negative patients with detectable HBV DNA at
the first presentation) were recruited. Another 11 serum samples
were collected from HBsAg-positive treatment-naı¨ve CHB patients
as controls. These subjects were first identified by testing their
blood samples for HBsAg (Abbott Prism, Abbott Laboratories,
Abbott Park IL) and by the nucleic acid amplification test (NAT)
for HBV DNA (Procleix Trigis system, Novartis Diagnostics,
Emeryville, CA; 95% detection limit, 12.2 IU/ml). Serum HBV
DNA levels were measured using the COBAS TaqMan HBV
Monitor Test (Roche Diagnostics, Branchburg, NJ), with a lower
limit of detection of 20 IU/ml (100 copies/ml). HBV DNA levels
in the liver biopsies were measured by real-time PCR using the
Artus HBV RG assay (Qiagen), which has a linear range of
detection of 1.1 IU/ml to .46109 IU/ml. The present study was
approved by the Institutional Review Board, the University of
Hong Kong, Hong Kong. Written informed consent was obtained
from all patients.
Rolling Circle Amplification and Sequencing of Full-
length HBV Genome
RCA, a powerful PCR-based technique for the amplification of
low viral load circular DNA, has been previously described [24].
Briefly, HBV plus-strand DNA inside the virions in the serum was
completed using the endogenous HBV polymerase before
extraction using the QIAamp MinElute Virus Vacuum Kit
(Qiagen). Nicks in the HBV DNA strands were then completed
by ligase (Epicentre, Madison, WI). For the liver biopsy samples,
total DNA was extracted using the QIAamp Allprep Kit (Qiagen).
The HBV DNA samples were subjected to RCA using eight
primers spanning the whole HBV genome (Table S1) [24]. Single
genome-length HBV DNA was either retrieved directly by SpeI
digestion (New England Biolabs) or further amplified using the
Expand High Fidelity PCR system (Roche, Mannheim, Germany)
[25]. This amplified HBV DNA was then purified and sequenced
using sequencing primers that cover the whole viral genome
(Table S1). Sensitivity and conditions for RCA reaction were
tested against samples with known copies of viral DNA (quantified
by the Artus real-time PCR kit; Qiagen).
Nucleotide Sequence and Amino Acid Analysis
Full-length HBV sequences were assembled using the CLC
Main Workbench 6.6.2 (CLC Bio, Katrinebjerg, Denmark). HBV
genotype was determined using the NCBI genotyping tool and
phylogenetic analysis. HBV sequences from OBI subjects were
compared with either sequences from the control subjects or
genotype-matched HBV sequences of Chinese CHB patients
retrieved from the GenBank [26]. Analysis of nucleotide and
amino acid diversity (d), as well as phylogenetic analysis, was
performed using the MEGA version 5 software [27]. The program
SimPlot [28] was used to search for evidence of recombination.
Amino acid mutation frequency was defined as the number of
amino acid variations per total number of amino acid residues
within a particular genomic region. Prediction of RNA secondary
structure was performed using the MFOLD software [29].
In-vitro Analysis on the Effects of Genetic Mutations on
Specific Regulatory Regions on HBV Promoter Activities
HBV promoter regions from selected OBI cases and wilde-type
controls were amplified using primers containing KpnI and NheI
restriction sites. The KpnI- and NheI-digested PCR products,
containing different mutated HBV promoter regions, were cloned
into the reporter vector pGL3-Basic. Positive constructs were
confirmed and co-transfected with pRL-TK Renilla reporter
plasmid into Huh-7 cells using Lipofectamine 2000 (Invitrogen).
After 24 hours of incubation, the cells were assayed for luciferase
activity using the Dual-Luciferase Reporter Assay System
(Promega, Madison, WI). Promoter activities were expressed as a
ratio of firefly luciferase to Renilla luciferase luminescence. Results
were expressed in arbitrary units (AU).
Statistical Analyses
Differences between categorical variables were analyzed using
the Fisher’s exact test or Chi-square test. For continuous variables,
the Student’s t-test was used. All statistical analysis was done using
GraphPad Prism 5.0 (GraphPad Software, Inc. San Diego, CA).
Data are expressed as percentage or mean 6 SD. A p-value of ,
0.05 was considered to be statistically significant.
Results
Rolling Circle Amplification for HBV Genomes from OBI
By using known copies of HBV DNA isolated from CHB
patients, we demonstrated RCA could amplify down to 15 copies/
reaction (Figure 1). Full-length HBV genomes were successfully
amplified from 18/60 (30%) liver biopsies and 4/185 (2.2%)
serum samples from OBI subjects using this RCA method.
Complete HBV genomes were also amplified from all 11 controls.
Seventeen out of these 18 OBI subjects had detectable intrahe-
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patic HBV DNA levels (median: 4.07 copies/cell; range: 0.07–
15.34 copies/cell). HBV viral load in the 4 serum samples were all
under the detection limit of COBAS assay of 20 IU/ml. Full-
length HBV genomes were also amplified from 11 HBsAg-positive
controls (median: 3.516105 IU/ml; range: 100–7.346107 IU/
ml).
Demographic Data and Phylogenetic Analysis
Demographic data of the study subjects are summarized in
Table 1. Genotype C was dominant in both OBI group (17/22;
77.3%; 11 with subtype C1, 4 with subtype C2 and 2 outliers) and
controls (9/11; 81.8%; all subtype C1). Genotype B was detected
in the remaining OBI subjects (5/22; 22.7%; all subtype B2) and
controls (2/11; 18.2%; 1 with subtype B2 and 1 outlier) (Figure
S1). Evidence of intergenotypic recombination between genotypes
B/C was detected in these 3 outliers but only constituted less than
20% of the major parental genotype. The full-length HBV
genomes and multiple sub-genomic regions reproduce the same
genotyping results, these 3 outliers (2 occult samples and 1 control)
were clustered into genotype C and B respectively. Of note,
phylogenetic analysis based on the full-length HBV sequences or
the 4 individual ORFs cannot distinctly separate OBI from CHB
controls (data not shown).
Comparison of HBV Genomic Diversity between OBI and
Control Subjects
The nucleotide and amino acid diversity were evaluated with
respective to their genotypes. The nucleotide diversity over the
entire HBV genome with genotype C was significantly higher in
the 17 subjects with OBI when compared with the 9 control
subjects (diversity, d = 0.04060.002 vs. 0.02660.002, p = 0.008).
The nucleotide diversity in these 17 OBI subjects was also
significantly higher than that in 49 genotype C reference
sequences retrieved from Chinese CHB patients [26]
(d = 0.0460.002 vs. d = 0.03060.001, p = 0.025). There was no
significant difference in the nucleotide diversity between OBI and
control subjects with genotype B (d = 0.02160.002 vs.
d = 0.01660.002, p = 0.279), which may be related to limited
number of tested subjects (n = 5 and n = 2, respectively). Similarly,
the nucleotide diversity between OBI subjects and 5 genotype B
reference sequences retrieved from Chinese CHB patients showed
no significant difference (d = 0.01660.002 vs. d = 0.01560.002,
p = 0.792) [30] (Table 2). In terms of amino acid diversity, there
Figure 1. Rolling circle amplification (RCA) of full-length HBV genome. The number of initial HBV DNA template present in each RCA
reaction is shown at the top. M, molecular weight marker; H2O, negative control. (A) The high-molecular-weight raw RCA products containing
multiple copies of the initial HBV template. (B) The full-length HBV genomes recovered by restriction enzyme, SpeI digestion. (C) Full-length HBV
genome amplified by using the RCA products as PCR template.
doi:10.1371/journal.pone.0099028.g001
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was no significant difference between OBI and control sequences
for both genotypes (data not shown).
Further analysis on the nucleotide and amino acid diversity on
the 4 individual HBV ORFs indicated OBI cases presented slightly
higher nucleotide and amino acid diversity than control cases
(Table 2). For genotype C cases, the nucleotide diversity in the pre-
S1, pre-C and P ORFs was significantly higher in OBI than
control cases (p= 0.048, p= 0.047 and p= 0.032, respectively). For
genotype B cases, OBI subjects had a significantly higher
nucleotide diversity in the pre-C/C and C regions (p = 0.045
and p= 0.031, respectively) (Table 2), and in the RNase H region
(p = 0.049) of the P ORF than control subjects (data not shown).
Furthermore, the difference in the nucleotide diversity between
OBI and control groups with genotype C in both pre-S/S and pre-
C/C regions also showed a similar trend (p = 0.069 and p = 0.059,
respectively) (Table 2). There was no significant difference on the
amino acid diversity between OBI and control sequences on the
4 ORFs in both genotypes (data not shown). In summary, OBI
Table 1. Clinical characteristics of the study subjects with full-length HBV genome amplified by rolling circle amplification (RCA).
OBI group Control group P-value
(n=22) (n=11)
Age
Mean 6 SEM 49.1866.16 54.91616.54 0.156
Gender
Male : Female 13: 9 5:6 0.488
HBV genotype (%)
B 5 (22.7%) 2 (18.2%)
C 17 (77.3%) 9 (81.8%) 0.763
Mutation frequency in the HBV key regulatory elements
Enhancer I 17 (77.3%) 6 (54.5%) 0.240
Enhancer II 7 (31.8%) 3 (27.3%) 1.000
DR 1 1 (4.5%) 0 (0%) n.a.
DR 2 0 (0%) 0 (0%) n.a.
Pre-S1 promoter 11 (50.0%) 7 (63.6%) 0.712
Pre-S2 promoter 14 (63.6%) 6 (54.5%) 0.714
Core Promoter 22 (100%) 10 (91.0%) 0.333
X Promoter 12 (54.5%) 5 (45.5%) 0.721
(OBI, occult hepatitis B infection; n.a.: not applicable; SEM: standard error of the mean; DR: direct repeat).
doi:10.1371/journal.pone.0099028.t001
Table 2. Comparison of the nucleotide (nt.) diversity (6 SEM) on the HBV genome of occult hepatitis B and control subjects.
HBV regions Genotype B Genotype C
OBI Control P-value OBI Control P-value
Pre-S/S 0.00860.002 0.00660.002 0.490 0.03060.003 0.01860.003 0.069
Pre-S1 0.00960.003 0.00760.003 0.833 0.05360.007 0.02260.005 0.048*
Pre-S2 0.01160.005 0.00260.002 0.320 0.03260.008 0.02460.009 0.603
S 0.00760.002 0.00660.002 0.706 0.02060.003 0.01560.003 0.461
Pre-C/Core 0.02860.005 0.00960.003 0.045* 0.04160.004 0.02460.004 0.059
Pre-C 0.01760.010 0.01860.011 0.924 0.04360.013 0.01460.008 0.047*
Core 0.03060.005 0.00860.003 0.031* 0.04160.004 0.02560.004 0.099
P 0.01360.002 0.01460.002 0.911 0.03960.003 0.02660.002 0.032*
X 0.01660.004 0.03660.006 0.090 0.02760.004 0.01860.004 0.267
Pre-S1 promoter 0.02760.005 0.01160.003 0.110 0.05560.006 0.03460.005 0.097
Pre-S2/S promoter 0.01060.004 0.00860.003 0.684 0.05260.007 0.02060.005 0.037*
Full-length HBV 0.02160.003 0.01660.002 0.279 0.04060.002 0.02660.002 0.008*
D Full-length HBV 0.01660.002 0.01560.002 0.792 0.04060.002 0.03060.002 0.025*
DFull-length HBV: OBI sequence compared with 5 genotype B and 49 genotype C reference sequence obtained from Chinese patients with chronic HBV infection. *A
statistical difference with p,0.05.
doi:10.1371/journal.pone.0099028.t002
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cases had a higher nucleotide diversity than control cases, and
these changes were scattered over the entire viral genome and may
not lead to coding changes. This was evidenced by the comparable
amino acid diversity between the two groups.
Mutational Analysis on the pre-S/S Coding Region
Details of the mutations observed in subjects with OBI and
CHB infection were illustrated in Table S2. The total number of
amino acid variations over the entire PreS/S region was
significantly higher in OBI than control cases [89/400 (22.2%)
vs. 33/400 (8.25%), p,0.0001] (Figure 2). The number of amino
acid substitutions in individual pre-S1, pre-S2 and S regions were
also significantly higher in OBI than control cases [pre-S1:21/119
(17.6%) vs. 3/119 (2.5%), p,0.0001; pre-S2:20/55 (36.4%) vs. 7/
55 (12.7%), p,0.001; S: 48/226 (21.2%) vs. 23/226 (10.2%), p,
0.001], respectively (Figure 2B). Some mutation patterns were
uniquely observed in OBI cases in pre-S/S ORF, including
sequence deletions (3/22, 13.6%) and abolishment of the pre-S2
start codon (ATG) by a point mutation (3/22, 13.6%). The
analysis of S ORF showed that the clinically important amino acid
substitutions were mainly located in the major hydrophilic region
(MHR) (residues 103–173). These included I126S, I126N,
Q129N, T131N, M133T, G145A and A159V. Except for
A159V, all the other 6 amino acid substitutions in MHR reside
in the ‘‘a’’ determinant region (residues 124–147) of the HBsAg,
and were found more frequently in OBI than control cases [5/24
(20.8%) vs. 2/24 (8.3%), p = 0.416]. Among them, I126S, Q129N
and M133T are associated with diagnostic problems [15,31,32],
whereas G145A is known as vaccine escape mutant and associated
with OBI [33].
Mutational Analysis on the pre-C/C Coding Regions
The number of amino acid substitutions in OBI cases was
significantly higher than control cases in both pre-C and core
ORFs (pre-C: 18/29 (62.1%) vs. 3/29 (10.3%); core: 99/183
(54.1%) vs. 37/183 (20.2%), both with p,0.0001) (Figure 3A, 3B
and Table S2). Within the pre-C region, the G1896A mutation
introducing a stop signal at codon 28 (W28*), which abolishes
HBeAg production was found in 7/22 occult cases and 1/11
control cases (31.8% vs. 9.1%, p = 0.2176) (Figure 3B). Mutations
in core region were mainly presented within different antigen
immunogenic epitopes. As shown in Figure 3B, OBI cases had a
higher number of amino acid substitutions than control cases
within the CD8+ CTL-epitope (residues 18–27) [6/10 (60%) vs.
1/10 (10%), p = 0.0573] and CD4+ T-cell epitope (residues 48–69)
[9/22 (40.9%) vs. 3/22 (13.6%), p = 0.0883]. Similarly, multiple
amino acid substitutions were also detected within the HBcAg
domain (residues 80–120). In particular, 9 amino acid changes
(S74G, E77D, E77Q, P79Q, A80T, E83D, L84A, S87G and
S87R) within the HBc/e1 epitope (residues 75–90) were solely
detected in OBI cases (56.3% vs. 0%, p,0.015), and that was
known to reduce both HBe and HBc antigenicity [34]. In addition,
amino acid substitutions within the HBc/e2 epitope (residues 120–
Figure 2. Schematic representation showing types and positions of mutations affecting the HBV pre-S/S region. (A) Binding sites in
the pre-S1 and pre-S2/S promoters for the liver-specific transcription factors (HNF1 and HNF3), Sp1, TATA binding protein (TBP) and the CCAAT box.
Distinct mutations in TF binding sites (broken arrows), premature termination of surface protein synthesis (*), nucleotide duplication (broken arrows),
deletion (a flash) and abolishment of pre-S2/S start codon (X) were indicated. (B) Amino acid changes in the pre-S1, pre-S2 and S genes. (Position with
more than one amino acid changes was bracketed. Amino acid changes in ‘‘a’’ determinant region were underlined).
doi:10.1371/journal.pone.0099028.g002
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140) in OBI cases were also higher than controls [5/21 (23.8%) vs.
2/21 (9.52%), p,0.041].
Mutational Analysis on the X Coding Region
The total number of amino acid substitutions in the X ORF was
significantly higher in subjects with OBI than controls [83/154
(53.9%) vs. 56/154 (36.4%), p,0.005]. A number of amino acid
mutations were solely detected in subjects with OBI, including
G22S (13.6%), P38S (13.6%), A102T (13.6%) and K118T
(13.6%). There was a trend of a higher frequency of H86R
mutation detected in OBI than in control cases [12/22 (54.5%) vs.
2/11 (9.1%), p = 0.067].
Mutational Analysis on the P Coding Region
The total number of amino acid substitutions over the P ORF
was significantly higher in OBI than control cases [197/843
(30.1%) vs. 63/843 (7.6%), p,0.0001] (Table S2). Deletions in the
pre-S/S region which lead to deletions and truncated proteins in
the overlapping P coding region were found in 3/22 (13.6%) OBI
cases. 3 out of 6 (50%) mutations detected in ‘‘a’’ determinant
region of HBsAg also caused mutation in overlapping rt region,
these included sI126S to rtD134E, sQ129N to rtS137Q and
sT131N to rtN139K (Figure 2B). Nucleotide T128A mutation in
the finger domain of the rt was uniquely detected in 3/22 (13.6%)
OBI cases. It is speculated that rtT128A mutation might result in
defective replication activity [35].
Distinct Mutations in the Regulatory Regions
The mutation frequency within the HBV key regulatory regions
was comparable between the OBI group and control group
(Table 1). However, a significant difference in the nucleotide
diversity was noticed over the pre-S2/S promoter when compar-
ing the OBI with the control groups with genotype C (p = 0.037;
Table 2). Point mutations were the most noticeable changes that
Figure 3. Schematic diagrams showing types and positions of the mutations affecting the overlapping HBV key regulatory regions.
(A) The overlapping regions of HBV genome contain core promoter (CP), basal core promoter (BCP), enhancer II (Enh II), DR1 (nt 1824–1834) and DR2
(nt 1590–1600) and coding regions of preC/C and X proteins. Clinically important mutations in BCP that results in the alteration of HNF1 binding site
and the corresponding amino acid changes in the overlapping X gene. (aa: amino acid, nt: nucleotide, DR: direct repeat). Distinct mutations in TF
binding sites, premature termination of protein synthesis, nucleotide duplication and deletion were indicated. Percentage of X mutants in
overlapping regions in occult and control cases were listed. (B) Amino acid changes in the pre-C and core genes. (Position with more than one aa
changes was bracketed).
doi:10.1371/journal.pone.0099028.g003
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scattered over these key regulatory elements. Most of them result
in interference with liver specific transcription factor (TF) binding
sites and were more frequently detected in OBI cases than controls
(Figure 2A, Figure 3A and Table S3). Large deletions at nt position
3127–55, 728–1255 and 1754–1771 were found in 3/22 (13.6%)
OBI cases. These deletions led to loss of pre-S2/S and X
promoters and disruption of BCP promoters, respectively. It is
noteworthy that unique nucleotide duplications at the promoter
regions were observed in 2/22 (9.1%) OBI cases. These unique
nucleotide duplications included a 21 nt duplication (nt 3107–
3127) in the Sp1 binding sites within the pre-S2/S promoter and a
31 nt duplication (nt 1644–1674) that interrupted the essential
element box b in enhancer II (Table S3) [36].
Recent studies suggested that pre-S2/S mRNA splicing is
essential for HBsAg expression [20,22]. This RNA splicing event is
controlled by a 59 splice donor site (nt 426–464) and the post-
transcriptional element (PRE) that contains the 39 splice acceptor
site. Nucleotide G458A mutation was found to influence HBV
RNA splicing and HBsAg production [20]. No G458A mutation
was detected in this study. One OBI case with both T429C and
T441G mutations in the 59 splice donor site, which were predicted
to affect mRNA secondary structure by MFOLD (Figure 4) [20].
The influence of RNA secondary structure on the activity of a
59splice site of the S mRNA and optimal production of HBsAg
needs further functional analysis.
Functional Analysis of the Distinct Nucleotide Alterations
in Regulatory Elements
We next explored whether the distinct surface promoter and
core promoter (CP) mutations identified in OBI cases caused a
change in their level of transcription activity. Based on the findings
of the mutations in the regulatory regions in OBI cases, 5 mutants
and two wild-type controls were constructed. These included
T2768A mutation located in Sp1 binding sites of pre-S1 (MUT1),
21 nt duplication between 3128–3148 on pre-S2/S (MUT2),
C3015T mutation on preS2/S (MUT3) and two mutations
G1677A (MUT4) and C1706T (MUT5) in CP. Luciferase
activities of the plasmids containing these mutant promoters
(MUT1–5) were compared to that of their corresponding wild-
type promoter. The absolute luciferase activity of the control wild-
type promoter was set to 100% and all the other mutant constructs
were compared accordingly. As shown in Figure 5, mutation
significantly affected the promoter activity in MUT2 (85%, p,
0.05), but not in MUT1 (92%, p = 0.226) and MUT3 (87%,
p = 0.156). The promoter activity was significantly decreased in
MUT4 (72%, p,0.05) and MUT5 (40%, p,0.005) with
respective to the control CP.
Discussion
We performed mutational analysis of the RCA-amplified full-
length HBV genomes from OBI and control cases. In order to
exclude natural polymorphism and/or differences related to the
geographical origin of the patients, it is imperative to have a robust
comparison of sequences obtained from cases with the same
genotype and origin. In this sense, we compared OBI sequences
with both genotype-matched controls and reference sequences
obtained from 49 genotype C (39 with sub-genotype C1 and
10 with sub-genotype C2) [26] and 5 genotype B2 CHB patients
from Hong Kong [30].
Our full-length HBV sequence analysis revealed that HBV
nucleotide diversity in OBI cases was significantly higher than
control cases, indicating that more sequence variations were
Figure 4. Prediction of RNA secondary structure at the 59 splice site of occult hepatitis B virus infection (OBI) and control HBV
strain. (A) RNA structure around the 59 splice site at position 458 in control wild-type HBV strain (B) Predicted RNA structure of the OBI case with
nucleotide T429C and T441G mutations. (Mutations are encircled and an arrow indicates the splice site).
doi:10.1371/journal.pone.0099028.g004
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observed in OBI. Despite the strict criteria, a variety of mutations
have been detected which are scattered throughout the viral
genome in both occult and overt cases. Many of the mutations
identified were in the surface proteins (Figure 2), which affect
HBsAg detection assays, immune response recognition, HBV
infectivity and virion morphogenesis [15,20,23]. However, we did
not identify any single prevailing mutation or genetic signature
which was associated with OBI. In this study, a mixture of
mutation patterns like point mutations, deletions and nucleotide
duplications were identified in OBI cases. This finding of multiple
mutations, rather than prevailing mutations or genetic signatures,
in OBI cases, is consistent with other reports [15,16,20,21,23,37].
This is further confirmed by our mutation frequency analysis that
the amino acid mutation frequency within the individual genes
and regulatory regions in the OBI cases was higher than that in the
control cases. Taken together, it is likely that OBI is attributed to
an increased accumulation of mutations in multiple regions,
including key regulatory and coding regions, which in turn
disrupts HBV replication and gene expression.
Despite the lack of prevailing OBI-associated mutations, this
study identified several unique mutations within the HBV
regulatory regions that may affect HBV replication. Many of
these mutations identified in the key regulatory regions reside in
the TF binding sites, which may disrupt TF bindings and hence
affect promoter functions (Figure 2A and 3A). The reduced
promoter activity was demonstrated in vitro by our luciferase
assay, which showed that core promoter activity was reduced with
G1677A mutation in TF HNF3 binding sites and with C1706T
mutation in the enhancer II region. We have also identified 2 OBI
cases with duplications of HBV regulatory sequence. To our
knowledge, this is the first description of nucleotide duplication in
regulatory elements in OBI. This may explain the significant
decrease in the pre-S2/S promoter activity caused by a 21 nt
duplication between 3128–3148 by the luciferase assay.
This study also identified mutations in the ‘‘a’’ determinant
region of the preS/S ORF in OBI subjects. Many mutations
identified in the pre-S/S ORF, especially within the ‘‘a’’
determinant, have been demonstrated to affect the antigenicity
and production of HBsAg, and thus possibly contribute to OBI
[20,23,38,39]. This study identified an OBI case with the sG145A
mutation, a vaccine escape variant which has been associated with
OBI [33]. In addition, point mutations leading to the abolishment
of pre-S2/S start codon and early stop signals, and sequence
deletions resulting in truncated surface protein synthesis were also
found in OBI cases. Xu et al. first reported that expression of a
pre-S1 mutant would result in intracellular retention of HBsAg
and that an appropriate balance of the various HBV surface
proteins was important for functional HBsAg production and
secretion [40,41]. Therefore, it is possible that the novel mutation
patterns identified in the present study may disrupt surface protein
synthesis and secretion. Of note, the change from sW182 to a stop
codon (W182*) was identified in an occult case, which was recently
suggested to be associated with OBI [42].
Due to the overlapping arrangement of HBV ORFs, mutations
in the pre-S/S region could lead to amino acid changes in the
overlapping P gene, especially in reverse transcriptase (rt). In
particular, three immune escape mutations identified in ‘‘a’’
determinant region in OBI cases also caused mutations in the
overlapping rt functional domains, including sI126S R rtD134E,
sQ129NR rtS137Q and sT131NR rtN139K. The effect of these
rt mutations on HBV replication level remains to be proven by
further in vitro analysis.
Mutations associated with post-transcriptional regulation of
HBsAg production were detected in OBI cases. The mechanism
for the newly identified post-transcriptional regulation of HBsAg
expression is still not yet fully elucidated. We have identified one
occult case with T429C and T441G mutation at the 59 donor
splice site, which may affect the preS/S RNA secondary structure.
As inhibition of HBsAg production could result from the mutation
occurred in the pre-S2/S splicing sites [20,22,43], further
investigation in larger OBI samples are needed.
In conclusion, our results indicated that subjects with OBI had a
higher genetic diversity and higher mutation frequency than
control subjects. The mutations identified in OBI cases included
point mutations and sequence deletions, which might cause
premature gene termination, defective HBsAg synthesis, decreased
HBV promoter activity, or reduced HBV replication. All these
mutations constrain viral replication capacity, and may collectively
contribute to the OBI entity among the HBsAg-negative subjects.
It is likely that multiple mechanisms are involved, and a
combination of mutations, rather than any prevailing genetic
signatures, is responsible for the OBI status.
Supporting Information
Figure S1 Phylogenetic analysis using the entire HBV
genomes amplified from the 22 occult and 11 control
HBV infected subjects. The filled circles represent the occult
subjects, and the empty circles represent control subjects.
Phylogenetic comparison was done by neighbor-joining algorithm
based on Kimura two-parameter distance estimation. Bootstrap
Figure 5. The relative luciferase activities of the constructs
were determined in Huh-7 cells. (A) The HBV sequences showing
type and position of the mutations in the constructs. (B) The relative
luciferase activity in the mutant constructs. Error bars indicate the
standard deviations. The luciferase activity of the wild-type (WT) was set
to 100% and the changes with the different mutants were calculated
accordingly.
doi:10.1371/journal.pone.0099028.g005
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values more than 75% are indicated on the major nodes. The scale
of the evolutionary distances is shown at the bottom (scale bar).
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